Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Formula | C24H27F2N5O4 |
|||
Molecular Weight | 487.50 | CAS No. | 1513857-77-6 | |
Solubility (25°C)* | In vitro | DMSO | 40 mg/mL (82.05 mM) | |
Water | Insoluble | |||
Ethanol | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
Description | Pemigatinib is an orally active and selective inhibitor of FGFR with IC50 of 0.4 nM, 0.5 nM, 1.2 nM and 30 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma. | ||||||||
---|---|---|---|---|---|---|---|---|---|
Targets |
|
||||||||
In vitro | Pemigatinib successfully diminishes the capacity of reactive astrocytes to recruit myeloid cells. Potentially FGFR modulation by pemigatinib may be promising for suppression of proinflammatory astrocyte responses while, at the same time, promoting protective mechanisms in murine and human systems.[2] |
||||||||
In vivo | No effect of pemigatinib on the disease course is evident on acute EAE.[2] |
Cell Assay: |
|
---|---|
Animal Study: |
|
|
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer [ Cancer Discov, 2023, 13(9):1998-2011] | PubMed: 37377403 |
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer [ Cancer Discov, 2023, 13(9):1998-2011] | PubMed: 37377403 |
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer [ Cancer Discov, 2023, 13(9):1998-2011] | PubMed: 37377403 |
A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma [ Mol Ther Nucleic Acids, 2023, 34:102047] | PubMed: 37869260 |
Distinct mechanisms for sebaceous gland self-renewal and regeneration provide durability in response to injury [ Cell Rep, 2023, 42(9):113121] | PubMed: 37715952 |
Coordinated inheritance of extrachromosomal DNA species in human cancer cells [ bioRxiv, 2023, 2023.07.18.549597] | PubMed: 37503111 |
Distinct mechanisms for sebaceous gland self-renewal and regeneration provide durability in response to injury [ bioRxiv, 2023, 2023.05.05.539454] | PubMed: 37205445 |
EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma [ Cancer Discov, 2022, 12(5):1378-1395] | PubMed: 35420673 |
Intranasal delivery of a small-molecule ErbB inhibitor promotes recovery from acute and late-stage CNS inflammation [ JCI Insight, 2022, 7(7)e154824] | PubMed: 35393953 |
Carcinoma of unknown primary: Molecular tumor board-based therapy [ CA Cancer J Clin, 2022, 2(6):510-523.] | PubMed: 36006378 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.